Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck, Matthew W. D. Perry, Jennifer R. Brown, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 10, pp. 741-769
Open Access | Times Cited: 335

Showing 1-25 of 335 citing articles:

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 704
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Yan Peng, Yuanyuan Wang, Cheng Zhou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 447
Phosphoinositides as membrane organizers
York Posor, Wonyul Jang, Volker Haucke
Nature Reviews Molecular Cell Biology (2022) Vol. 23, Iss. 12, pp. 797-816
Open Access | Times Cited: 240
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
Huayi Li, Lorenzo Prever, Emilio Hirsch, et al.
Cancers (2021) Vol. 13, Iss. 14, pp. 3517-3517
Open Access | Times Cited: 135
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 134
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Neil Vasan, Lewis C. Cantley
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 7, pp. 471-485
Open Access | Times Cited: 112
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 440-462
Closed Access | Times Cited: 96
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Kunrui Zhu, Yanqi Wu, Ping He, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2508-2508
Open Access | Times Cited: 95
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Yi Wang, Kai Conrad Cecil Johnson, Margaret E. Gatti‐Mays, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 93
Molecular and functional imaging in cancer-targeted therapy: current applications and future directions
Jing‐Wen Bai, Si-Qi Qiu, Guo‐Jun Zhang
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 93
Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries
Antonella Montinaro, Henning Walczak
Cell Death and Differentiation (2022) Vol. 30, Iss. 2, pp. 237-249
Open Access | Times Cited: 75
Atropisomerism in Drug Discovery: A Medicinal Chemistry Perspective Inspired by Atropisomeric Class I PI3K Inhibitors
Stéphane Perreault, Jayaraman Chandrasekhar, Leena Patel
Accounts of Chemical Research (2022) Vol. 55, Iss. 18, pp. 2581-2593
Closed Access | Times Cited: 73
Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions
Jindi Huang, Liye Chen, Jiangxia Wu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16033-16061
Closed Access | Times Cited: 73
Beyond PI3Ks: targeting phosphoinositide kinases in disease
John E. Burke, Joanna Triscott, Brooke M. Emerling, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 5, pp. 357-386
Open Access | Times Cited: 72
A small-molecule PI3Kα activator for cardioprotection and neuroregeneration
Grace Q. Gong, Benoît Bilanges, Ben Allsop, et al.
Nature (2023) Vol. 618, Iss. 7963, pp. 159-168
Open Access | Times Cited: 55
Targeting Breast Cancer: An Overlook on Current Strategies
Domenico Iacopetta, Jessica Ceramella, Noemi Baldino, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3643-3643
Open Access | Times Cited: 44
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Muhammad Tufail, Jia-Ju Hu, Jie Liang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
Zhi Qi, Zihan Xu, Liuzhen Zhang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 67
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 61
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma
Manfei Pi, Huixian Kuang, Chunyan Yue, et al.
Drug Resistance Updates (2022) Vol. 61, pp. 100822-100822
Closed Access | Times Cited: 57
PI(4,5)P2: signaling the plasma membrane
Rachel C. Wills, Gerald Hammond
Biochemical Journal (2022) Vol. 479, Iss. 21, pp. 2311-2325
Open Access | Times Cited: 55
PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression
Shuo Deng, Hin Chong Leong, Arpita Datta, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1652-1652
Open Access | Times Cited: 52
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Simon Eschweiler, Ciro Ramírez-Suástegui, Yingcong Li, et al.
Nature (2022) Vol. 605, Iss. 7911, pp. 741-746
Open Access | Times Cited: 52
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα
Chiara Borsari, Erhan Keleş, Jacob A. McPhail, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 14, pp. 6326-6342
Open Access | Times Cited: 43
Dysregulated Amino Acid Sensing Drives Colorectal Cancer Growth and Metabolic Reprogramming Leading to Chemoresistance
Sumeet Solanki, Katherine Sanchez, Varun Ponnusamy, et al.
Gastroenterology (2022) Vol. 164, Iss. 3, pp. 376-391.e13
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top